Compare Théraclion SA with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
EUR 27 Million ()
NA (Loss Making)
NA
0.00%
-0.71
344.21%
-10.76
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2022)
Net Profit:
-3 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-76.91%
0%
-76.91%
6 Months
-76.33%
0%
-76.33%
1 Year
-59.27%
0%
-59.27%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Théraclion SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-13.93%
EBIT Growth (5y)
-8.44%
EBIT to Interest (avg)
-5.42
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.01
Sales to Capital Employed (avg)
0.33
Tax Ratio
18.73%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-12.03
EV to EBIT
-5.04
EV to EBITDA
-5.09
EV to Capital Employed
-19.72
EV to Sales
31.45
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Standalone) - Jun'22 - YoY
Jun'22
Jun'21
Change(%)
Net Sales
0.30
0.90
-66.67%
Operating Profit (PBDIT) excl Other Income
-3.40
-1.70
-100.00%
Interest
-0.00
0.20
-100.00%
Exceptional Items
0.30
-0.00
Standalone Net Profit
-2.60
-1.60
-62.50%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2022 is -66.67% vs 350.00% in Jun 2021
Standalone Net Profit
YoY Growth in quarter ended Jun 2022 is -62.50% vs 15.79% in Jun 2021
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
0.80
1.80
-55.56%
Operating Profit (PBDIT) excl Other Income
-6.60
-2.90
-127.59%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-5.80
-3.70
-56.76%
Operating Profit Margin (Excl OI)
-8,382.90%
-1,731.20%
-665.17%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -55.56% vs 50.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -56.76% vs 26.00% in Dec 2023
About Théraclion SA 
Théraclion SA
Pharmaceuticals & Biotechnology
Theraclion is a France-based company, which develops High Intensity Focused Ultrasound (HiFu) machines. The Company is a a spin-off of Inserm and EDAPTechomed. The main activity of the Company is developping, manufacturing and marketing echotherapy medical equipments associating therapy by focused ultrasound and monitoring by ultrasound. The Company provides Echopulse, a device for the non-invasive and outpatient treatment of the fibroadenoma of the breast and thyroid nodules.
Company Coordinates 
Company Details
102, rue Etienne Dolet , MALAKOFF None : 92240
Registrar Details






